Biotech and Pharmaceuticals Pharmaceuticals

More

  • Chartology: Is The Bottom In Wednesday, 1 Oct 2008 | 6:16 PM ET

    The Fast Money traders told you the bottom won’t be in, until there’s panic like never before. Wait...

  • While the Street is focused on the big vote in the Senate tonight on the bailout package, biotech investors will be on the lookout for news out of ImClone Systems. Earlier this week the company announced that its mystery counter-bidder will decide whether to follow through on its $70-a-share offer by midnight tonight.

  • The Waiting Game Continues For Lilly & ImClone Monday, 29 Sep 2008 | 10:42 AM ET
    lilly_hq.jpg

    Eli Lilly has been running direct-to-doctor ads over the past few months telling physicians that Effient, the company's new bloodthinner, is "Coming Soon". Well, it may have jumped the gun.

  • Lilly

    Today is the day the FDA is expected to make a decision on the drug. The agency could approve it outright, approve it with conditions/limitations, delay making a decision--again--and order more tests, or reject the pill.

  • Mardi Gras Beads

    There are reports of booze, women and beads--as in Mardi Gras beads. Specifically, the piece cites allegations from a lawsuit brought by a former MDT attorney who says the medical device maker sponsored a "discussion group" outing to New Orleans.

  • Heart Drugs Could Save Billions Over Stents: Study Wednesday, 24 Sep 2008 | 4:14 PM ET

    A first-of-its-kind study shows that putting hundreds of thousands of American heart patients on drugs instead of giving them a stent could save the country billions of dollars a year.

  • Bristol Vs. ImClone Heats Up As Icahn Gets Nastier Wednesday, 24 Sep 2008 | 9:18 AM ET
    bristol_myers_squibb.jpg

    I've been under the weather and too lethargic to even blog for a couple days, but nuthin' like a good ol' fashioned corporate war of words to get me goin' again.

  • Five Defensive Stocks for Hard Times Tuesday, 23 Sep 2008 | 8:42 AM ET

    Pharmas, energy, information technology and industrials are still good defensive plays, Grant Bowers, portfolio manager at Franklin Templeton Investments, told "Worldwide Exchange."

  • Oktoberfest on the Defensive Monday, 22 Sep 2008 | 10:12 AM ET
    Oktoberfest_11.jpg

    There are two types of seating at the Oktoberfest tents: reserved and unreserved. My attempt at entering the reserved seating was blocked by security, press pass notwithstanding.

  • Schering-Plough Slashes 1,000 Jobs To Reduce Costs Friday, 19 Sep 2008 | 5:55 PM ET

    Schering-Plough said Friday it will cut 1,000 sales jobs as part of broader cuts in a move to reduce costs and reposition itself in an ever-changing industry.

  • merck_manual.jpg

    As the press release that came with the book says, "Compact enough to carry in a lab coat pocket, the paperback helps health care practitioners, particularly those who are newcomers to clinical diagnosis, understand and evaluate a wide range of symptoms."

  • Pfizer Is A Driver: "Complaining" Investor Read On! Thursday, 18 Sep 2008 | 4:40 PM ET
    pfizer_hq.jpg

    The stock posted its biggest percentage gain in nearly three years and its biggest dollar gain in more than two years, according to CNBC stock-stat maven Robert Hum.

  • Lilly Loves Lechleiter--But Stock Moves On Other "News" Thursday, 18 Sep 2008 | 11:33 AM ET
    lilly_hq.jpg

    New Eli Lilly CEO John Lechleiter today joins the list of the recent fresh crop of big pharma honchos who've been elevated to Chairman of the Board as well. But that's not what's moving shares of LLY higher this morning.

  • Dendreon's "Naked Shorts" Running For Cover? Wednesday, 17 Sep 2008 | 3:15 PM ET
    dendreon_logo_new2.jpg

    Some readers will accuse me of finding any old excuse to write about Dendreon, which as I've blogged before always results in a spike in page views. But on a day when nearly all of biopharma is under pressure again due to market forces, it's truly worth calling attention...

  • Abbott & Boston Scientific: Rising Stent Stars Wednesday, 17 Sep 2008 | 12:21 PM ET
    Boston Scientific Corp.

    Not too long ago, some had written off the potential for significant growth to resume in sales of the little wire mesh tubes that are painted with special drugs to help keep arteries from reclogging.

  • Amgen's Embargo Victory Tuesday, 16 Sep 2008 | 12:30 PM ET
    Amgen

    This morning the world's biggest biotech company released the highly-anticipated detailed test results on its crucial, late-stage experimental osteoporosis drug known as D-mab. And they look good.

  • Putting My Finger On The BlackBerry Addiction Friday, 12 Sep 2008 | 2:03 PM ET
    splint.jpg

    Yesterday afternoon I became a statistic. I am now among the reportedly growing number of people getting injured while texting and--not driving--but walking.

  • ImClone-Bristol Battle Is Really Gettin' Good Friday, 12 Sep 2008 | 9:57 AM ET
    imclone_logo_new.jpg

    I finished my last ImClone Systems vs. Bristol-Myers Squibb entry asking what Bristol had to say about IMCL's claim of a mystery outbidder. Well, yesterday we found out in a press release from BMY.

  • Charts Point to European Drug Stocks Thursday, 11 Sep 2008 | 7:56 AM ET

    Of all the places to put money to work in Europe, the pharmaceutical sector is the most promising, a technical analyst told CNBC Thursday.

  • ImClone's Icahn: Holding A Pistol To Bristol Wednesday, 10 Sep 2008 | 12:05 PM ET
    Carl Icahn

    At the Thomson Reuters/BioCentury investment conference some hedge fund guy, who I'd never met before and who will remain unidentified, whispered in my ear that there's gonna be a bidding war for ImClone Systems.